{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:02:16Z","timestamp":1790935336985,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["S1101027"],"award-info":[{"award-number":["S1101027"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Immunology"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.cellimm.2013.04.011","type":"journal-article","created":{"date-parts":[[2013,5,4]],"date-time":"2013-05-04T13:15:40Z","timestamp":1367673340000},"page":"100-105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Lipopolysaccharide prevents valproic acid-induced apoptosis via activation of nuclear factor-\u03baB and inhibition of p53 activation"],"prefix":"10.1016","volume":"282","author":[{"given":"Bilegtsaikhan","family":"Tsolmongyn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Koide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erdenezaya","family":"Odkhuu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abedul","family":"Haque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Naiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Yokochi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cellimm.2013.04.011_b0005","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1517\/14656566.9.2.285","article-title":"Oral valproic acid for epilepsy-long-term experience in therapy and side effects","volume":"9","author":"Gerstner","year":"2008","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.cellimm.2013.04.011_b0010","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/jcb.22185","article-title":"Histone deacetylase inhibitors: potential in cancer therapy","volume":"107","author":"Marks","year":"2009","journal-title":"J. Cell Biochem."},{"key":"10.1016\/j.cellimm.2013.04.011_b0015","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.biocel.2008.09.008","article-title":"Histone deacetylase inhibitors: anticancer compounds","volume":"41","author":"Smith","year":"2009","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.cellimm.2013.04.011_b0020","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1038\/onc.2010.599","article-title":"Histone deacetylase inhibitors prime medulloblastoma cells for chemotherapy-induced apoptosis by enhancing p53-dependent Bax activation","volume":"30","author":"H\u00e4cker","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.cellimm.2013.04.011_b0025","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1158\/1541-7786.MCR-10-0471","article-title":"Low-dose valproic acid enhances radiosensitivity of prostate cancer through acetylated p53-dependent modulation of mitochondrial membrane potential and apoptosis","volume":"9","author":"Chen","year":"2011","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.cellimm.2013.04.011_b0030","first-page":"787","article-title":"Histone deacetylase inhibitors valproic acid and depsipeptide sensitize retinoblastoma cells to radiotherapy by increasing H2AX phosphorylation and p53 acetylation-phosphorylation","volume":"37","author":"Kawano","year":"2010","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.cellimm.2013.04.011_b0035","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/sj.bjp.0707608","article-title":"Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells","volume":"153","author":"Condorelli","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.cellimm.2013.04.011_b0040","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0065-230X(01)82002-9","article-title":"p53-Dependent apoptosis pathways","volume":"82","author":"Shen","year":"2001","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.cellimm.2013.04.011_b0045","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1038\/nature07986","article-title":"Cytoplasmic functions of the tumor suppressor p53","volume":"458","author":"Green","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.cellimm.2013.04.011_b0050","doi-asserted-by":"crossref","first-page":"a001883","DOI":"10.1101\/cshperspect.a001883","article-title":"Tumor suppressive functions of p53","volume":"1","author":"Zilfou","year":"2009","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.cellimm.2013.04.011_b0055","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/ni.1863","article-title":"The role of pattern-recognition receptors in innate immunity: update on toll-like receptors","volume":"11","author":"Kawai","year":"2010","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cellimm.2013.04.011_b0060","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11010-009-0267-2","article-title":"NF-kappaB and cancer: how intimate is this relationship","volume":"336","author":"Prasad","year":"2010","journal-title":"Mol. Cell Biochem."},{"key":"10.1016\/j.cellimm.2013.04.011_b0065","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/j.cellsig.2006.05.015","article-title":"Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: implications for cancer therapy","volume":"18","author":"Henson","year":"2006","journal-title":"Cell Signal."},{"key":"10.1016\/j.cellimm.2013.04.011_b0070","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1439-0531.2003.00438.x","article-title":"Apoptosis of granulosa cells: a review on the role of MAPK-signaling modules","volume":"38","author":"Peter","year":"2003","journal-title":"Reprod. Domest. Anim."},{"key":"10.1016\/j.cellimm.2013.04.011_b0075","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1158\/1541-7786.MCR-05-0046","article-title":"Lipopolysaccharide prevents doxorubicin-induced apoptosis in RAW 264.7 macrophage cells by inhibiting p53 activation","volume":"3","author":"Hassan","year":"2005","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.cellimm.2013.04.011_b0080","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.bbrc.2005.12.050","article-title":"Lipopolysaccharide prevents apoptosis induced by brefeldin A, an endoplasmic reticulum stress agent, in RAW 264.7 cells","volume":"340","author":"Islam","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.cellimm.2013.04.011_b0085","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.cellimm.2009.11.009","article-title":"B1 cells produce nitric oxide in response to a series of toll-like receptor ligands","volume":"261","author":"Tumurkhuu","year":"2010","journal-title":"Cell Immunol."},{"key":"10.1016\/j.cellimm.2013.04.011_b0090","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2567.2009.03154.x","article-title":"Tumor necrosis factor-a augments lipopolysaccharide-induced suppressor of cytokine signaling 3 (SOCS-3) protein expression by preventing the degradation","volume":"129","author":"Dagvadorj","year":"2010","journal-title":"Immunology"},{"key":"10.1016\/j.cellimm.2013.04.011_b0095","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0090-4295(98)00360-4","article-title":"Bcl-2\/Bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer","volume":"52","author":"Mackey","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.cellimm.2013.04.011_b0100","first-page":"90","article-title":"NF\u03baB\/p53 crosstalk-a promising new therapeutic target","volume":"1815","author":"Schneider","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.cellimm.2013.04.011_b0105","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/ijc.23324","article-title":"A signal network involving coactivated NF-kappaB and STAT3 and altered p53 modulates BAX\/BCL-XL expression and promotes cell survival of head and neck squamous cell carcinomas","volume":"122","author":"Lee","year":"2008","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.cellimm.2013.04.011_b0110","doi-asserted-by":"crossref","first-page":"240365","DOI":"10.1155\/2010\/240365","article-title":"Current views of toll-like receptor signaling pathways","volume":"2010","author":"Yamamoto","year":"2010","journal-title":"Gastroenterol. Res. Pract."},{"key":"10.1016\/j.cellimm.2013.04.011_b0115","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1600-065X.2008.00701.x","article-title":"The interleukin-1 receptor\/toll-like receptor superfamily: 10years of progress","volume":"226","author":"O\u2019Neill","year":"2008","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.cellimm.2013.04.011_b0120","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4149\/neo_2011_01_35","article-title":"Epigenetic modulation of gene expression of human leukemia cell lines \u2013 induction of cell death and senescence","volume":"58","author":"Elknerova","year":"2011","journal-title":"Neoplasma"},{"key":"10.1016\/j.cellimm.2013.04.011_b0125","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/1756-9966-29-149","article-title":"Effects of valproic acid on the cell cycle and apoptosis through acetylation of histone and tubulin in a scirrhous gastric cancer cell line","volume":"29","author":"Yagi","year":"2010","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.cellimm.2013.04.011_b0130","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1593\/neo.05823","article-title":"Valproic acid, an antiepileptic drug with histone deacetylase inhibitory activity, potentiates the cytotoxic effect of Apo2L\/TRAIL on cultured thoracic cancer cells through mitochondria-dependent caspase activation","volume":"8","author":"Ziauddin","year":"2006","journal-title":"Neoplasia"},{"key":"10.1016\/j.cellimm.2013.04.011_b0135","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0145-2126(01)00151-5","article-title":"Valproic acid induces apoptosis in human leukemia cells by stimulating both caspase-dependent and -independent apoptotic signaling pathways","volume":"26","author":"Kawagoe","year":"2002","journal-title":"Leuk. Res."},{"key":"10.1016\/j.cellimm.2013.04.011_b0140","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1023\/A:1007649815992","article-title":"Hepatotoxicity due to mitochondrial dysfunction","volume":"15","author":"Pessayre","year":"1999","journal-title":"Cell Biol. Toxicol."},{"key":"10.1016\/j.cellimm.2013.04.011_b0145","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1038\/nrd2759","article-title":"Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-kappaB pathways","volume":"7","author":"Dey","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.cellimm.2013.04.011_b0150","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1535-6108(02)00068-5","article-title":"P53 stabilization is decreased upon NFkappaB activation: a role for NFkappaB in acquisition of resistance to chemotherapy","volume":"1","author":"Tergaonkar","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cellimm.2013.04.011_b0155","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1096\/fj.04-3213fje","article-title":"P53 is a suppressor of inflammatory response in mice","volume":"19","author":"Komarova","year":"2005","journal-title":"FASEB J."},{"key":"10.1016\/j.cellimm.2013.04.011_b0160","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0092-8674(00)81589-5","article-title":"Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors","volume":"94","author":"Luo","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.cellimm.2013.04.011_b0165","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1517\/13543784.2012.694425","article-title":"Valproic acid for the treatment of malignant gliomas: review of the preclinical rationale and published clinical results","volume":"21","author":"Berendsen","year":"2012","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.cellimm.2013.04.011_b0180","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1517\/14656566.9.2.285","article-title":"Oral valproic acid for epilepsy-long-term experience in therapy and side effects","volume":"9","author":"Gerstner","year":"2008","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.cellimm.2013.04.011_b0175","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1002\/cncr.20709","article-title":"Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis","volume":"101","author":"Takai","year":"2004","journal-title":"Cancer"}],"container-title":["Cellular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874913000622?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874913000622?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T22:49:56Z","timestamp":1757803796000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008874913000622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S0008874913000622"],"URL":"https:\/\/doi.org\/10.1016\/j.cellimm.2013.04.011","relation":{},"ISSN":["0008-8749"],"issn-type":[{"value":"0008-8749","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipopolysaccharide prevents valproic acid-induced apoptosis via activation of nuclear factor-\u03baB and inhibition of p53 activation","name":"articletitle","label":"Article Title"},{"value":"Cellular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellimm.2013.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}